Latest Breaking News On - Gron ventures - Page 5 : comparemela.com

Gilgamesh Pharmaceuticals, a biotechnology company that uses psychedelic-related drugs to treat neuropsychiatric disorders, reported Thursday it has raised $27 million in a Series A funding round led by Prime Movers Lab. Other investors involved in the round included the Noetic Psychedelic Fund LP, Gron Ventures, Route 66 Ventures, JLS Fund and Palo Santo Investors. Prime Movers Lab, a partnership that invests in breakthrough scientific startups, is known for raising funds for inventors in energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture. With the newly raised capital, New York-based Gilgamesh plans to add more members to its team, including a COO, head of R&D and CBO. It will also work on advancing its programs toward clinical candidate selection and broadening its IP portfolio.

Amy kruseJonathan spornJeff witkinMike cunninghamAndrew kruegelNoetic psychedelic fundMovers labGilgamesh pharmaceuticalsPrime moversGron venturesPalo santoNew york based gilgameshPrime movers labDalibor samesஆமி க்ரூஸ்ஜொனாதன் ச்போர்ன்